The molecular landscape of prostate cancer is characterized by recurrent genomic alterations, including the fusion of ETS family genes such as ERG, ETV1, ETV4, or FLI1, and genetic mutations involving SPOP, FOXA1, or IDH1 [4]. This evidence concerns the gene FOXA1 and prostate carcinoma.